¼¼°èÀÇ ÇÙ»ê °Ë»ç ½ÃÀå
Nucleic Acid Testing
»óǰÄÚµå : 1513861
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 372 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,789,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇÙ»ê °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 44¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â 32¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è ÇÙ»ê °Ë»ç ½ÃÀåÀº 2023-2030³â µ¿¾È ¿¬Æò±Õ 4.6% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 44¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÙ»ê °Ë»ç ŰƮ´Â CAGR 5.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 37¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÙ»ê °Ë»ç ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 8¾ï 7,180¸¸ ´Þ·¯, Áß±¹Àº CAGR 7.8%·Î ¼ºÀå Àü¸Á

¹Ì±¹ ÇÙ»ê °Ë»ç ½ÃÀåÀº 2023³â 8¾ï 7,180¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â 7.8%ÀÇ CAGR·Î 2030³â±îÁö 9¾ï 5,080¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 1.2%¿Í 5.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 2.3%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÇÙ»ê °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

ÇÙ»ê °Ë»ç(NAT)´Â ½Ã·á¿¡¼­ DNA ¶Ç´Â RNAÀÇ Æ¯Á¤ ¿°±â¼­¿­À» °ËÃâÇÏ´Â µ¥ »ç¿ëµÇ´Â ÷´Ü »ý¹°ÇÐÀû ±â¼úÀÔ´Ï´Ù. ÀÌ ¹æ¹ýÀº ÀÇ·á Áø´Ü, ¹ýÀÇÇÐ, »ý¹°ÇÐ ¿¬±¸ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÇÙ»ê °Ë»ç(NAT)´Â ƯÈ÷ ÀÇ·á ºÐ¾ß¿¡¼­ ´Ù¾çÇÑ Áø´Ü ¹× ½ºÅ©¸®´× ¿ëµµ·Î »ç¿ëµÇ´Â Áß¿äÇÑ ºÐÀÚ ±â¼úÀÔ´Ï´Ù. Ç÷¾×, ¼Òº¯, Á¶Á÷¿¡ Á¸ÀçÇÏ´Â ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¹× ±âŸ º´¿øÃ¼¿¡¼­ DNA ¶Ç´Â RNAÀÇ Æ¯Á¤ ¿°±â¼­¿­À» °ËÃâÇϱâ À§ÇØ Ã·´Ü ±â¹ýÀ» Ȱ¿ëÇϰí ÀÖÀ¸¸ç, NAT ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ÀÇ·á Áø´Ü¿¡ ´ëÇÑ »ç¿ë Áõ°¡ÀÔ´Ï´Ù. Áúº´À» À¯¹ßÇÏ´Â ¹ÙÀÌ·¯½º³ª ¹ÚÅ׸®¾Æ µîÀÇ º´¿øÃ¼¸¦ °ËÃâÇÏ´Â °í°¨µµ ¹æ¹ýÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù. º´¿øÃ¼¿¡¼­ Á÷Á¢ À¯Àü ¹°ÁúÀ» °ËÃâÇÒ ¼ö Àֱ⠶§¹®¿¡ ¹è¾ç ±â¼ú°ú °°Àº ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ´õ ºü¸£°í Á¤È®ÇÑ Áø´ÜÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ´Â HIV, BÇü °£¿°, CÇü °£¿°, °áÇÙ, COVID-19¿Í °°Àº °¨¿°¼º ÁúȯÀÇ Áø´Ü¿¡ ƯÈ÷ Áß¿äÇϸç, Àû½Ã¿¡ Á¤È®ÇÑ °ËÃâÀº Ä¡·á °á°ú¿Í ȯÀÚÀÇ È¸º¹¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ÀÌ °Ë»ç¹ýÀÇ ´É·Â°ú Á¢±Ù¼ºÀ» Çâ»ó½ÃÅ´À¸·Î½á NAT ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR), ½Ç½Ã°£ PCR, Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS)ÀÇ °³¼±À¸·Î NATÀÇ Àû¿ë ¹üÀ§°¡ ³Ð¾îÁö°í ´õ ºü¸£°í Á¤È®ÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ °Ë»ç¹ýÀÌ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÈÞ´ë¿ë ¹× ÇöÀå Áø´Ü¿ë NAT ±â±âÀÇ °³¹ß·Î Áï°¢ÀûÀÎ Áø´ÜÀÌ °¡´ÉÇØÁü¿¡ µû¶ó ÀÌ ±â¼úÀÇ µµ´Þ ¹üÀ§°¡ ÀüÅëÀûÀÎ ½ÇÇè½Ç ȯ°æ¿¡¼­ ȯÀÚ Ä¡·á ½Ã³ª¸®¿À·Î È®ÀåµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ¿© Ä¡·á È¿°ú¿Í ȯÀÚ ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ Áõ°¡ Ãß¼¼¸¦ µÞ¹ÞħÇϰí ÀÖÀ¸¸ç, NAT´Â À¯ÀüÀÚÇü ºÐ¼®, ¾à¸®À¯ÀüüÇÐ, ¾ÏÀ¯ÀüüÇп¡¼­ ¸Å¿ì Áß¿äÇϸç, ƯÁ¤ Ä¡·á¹ýÀÇ È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â À¯ÀüÀÚ º¯À̸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ Á¤È®ÇÑ Á¢±Ù¹ýÀº Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸç ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

À¯ÀüÀÚ °Ë»ç, ¹ýÀÇÇÐ ºÐ¾ß¿¡¼­ÀÇ NAT Àû¿ë Áõ°¡, ±ÔÁ¦ ±â°ü ¹× Á¤ºÎÀÇ Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì·®ÀÇ À¯Àü¹°ÁúÀ» °ËÃâÇϰí Á¤·®È­ÇÒ ¼ö ÀÖ´Â NATÀÇ ´É·ÂÀº À¯ÀüÀÚ ¿¬±¸ ¹× Áø´Ü, ¹üÁË ¼ö»ç ¹× Àç³­ ÇÇÇØÀÚ ½Å¿ø È®Àΰú °°Àº ¹ýÀÇÇÐ ºÐ¾ß¿¡¼­ ¸Å¿ì À¯¿ëÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó Á¤È®ÇÏ°í ºü¸¥ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ NAT ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÇ·á ¹× °úÇÐ ¹ßÀü¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(46°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nucleic Acid Testing Market to Reach US$4.4 Billion by 2030

The global market for Nucleic Acid Testing estimated at US$3.2 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2023-2030. Nucleic Acid Test Kits, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Nucleic Acid Testing Consumables segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$871.8 Million While China is Forecast to Grow at 7.8% CAGR

The Nucleic Acid Testing market in the U.S. is estimated at US$871.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$950.8 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Nucleic Acid Testing Market - Key Trends and Drivers Summarized

Nucleic Acid Testing (NAT) is a sophisticated biological technique used to detect specific sequences of DNA or RNA in a sample. This method has become indispensable in various fields, including medical diagnostics, forensic science, and biological research. Nucleic Acid Testing (NAT) is a vital molecular technique employed in various diagnostic and screening applications, particularly in the medical field. It utilizes advanced methodologies to detect the specific sequences of DNA or RNA from viruses, bacteria, or other pathogens present in blood, urine, or tissues. One of the primary drivers of the NAT market is its increasing use in medical diagnostics. NAT offers a highly sensitive method for detecting pathogens, including viruses and bacteria that cause diseases. Its ability to detect genetic material directly from pathogens enables earlier and more accurate diagnosis compared to traditional methods like culture techniques. This is particularly critical in the diagnosis of infectious diseases such as HIV, hepatitis B and C, tuberculosis, and COVID-19, where timely and precise detection can significantly influence treatment outcomes and patient recovery.

Technological advancements are propelling the NAT market forward by enhancing the capabilities and accessibility of this testing method. Improvements in polymerase chain reaction (PCR), real-time PCR, and next-generation sequencing (NGS) have broadened NAT's applications, making it faster, more accurate, and cost-effective. Additionally, the development of portable and point-of-care NAT devices allows for immediate diagnoses, extending the technology's reach beyond traditional lab settings into immediate patient care scenarios. These innovations support the growing trend toward personalized medicine, where treatments are tailored based on individual genetic profiles, improving treatment efficacy and patient safety. NAT is crucial in genotyping, pharmacogenomics, and cancer genomics, helping to identify genetic mutations that may influence the effectiveness of certain therapies. This precise approach enhances treatment efficacy and minimizes adverse drug reactions, leading to better patient outcomes.

The increasing application of NAT in genetic testing, forensic science, and the support of regulatory bodies and governments further boost market growth. NAT's ability to detect and quantify minute amounts of genetic material makes it invaluable in genetic research and diagnostics, as well as in forensic applications for identifying individuals in criminal investigations and disaster victim identification. As technology continues to evolve, the demand for precise and rapid diagnostics is expected to drive substantial growth in the NAT market, affirming its integral role in healthcare and scientific advancements.

Select Competitors (Total 46 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â